 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Crescent Biopharma
CBIO
conference date: February 26, 2026, press release only
| 2025 | |||
| Crescent Biopharma Q2 2025 press release |
Crescent Biopharma Q3 2025 press release |
Crescent Biopharma Q4 2025 press release |
|
| Q2 2025 | Q3 2025 | Q4 2025 | |
Crescent Biopharma is a preclinical-stage biotechnology company specializing in cancer therapies. It went public on June 16, 2025 by acquiring Glycomimetics.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| BOLD |
| CCCC |
| CLDX |
| CBIO |
| FATE |
| GILD |
| ILMN |
| INCY |
| INKT |
| INO |
| IONS |
| IOVA |
| LGND |
| MCHP |
| MRNA |
| PASG |
| REGN |
| RXRX |
| SANA |
| SUPN |
| VRTX |
| VSTM |
| XNCR |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2026 William P. Meyers